Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Profile Name||ERBB2 G776_V777insVC|
|Gene Variant Detail|
|Relevant Treatment Approaches||HER inhibitor (Pan) HER2 Inhibitor|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ERBB2 G776_V777insVC ERBB2 over exp||lung non-small cell carcinoma||predicted - sensitive||Ado-trastuzumab emtansine||Case Reports/Case Series||Actionable||In a Phase II trial, a non-small cell lung cancer patient with ERBB2 overexpression (IHC 3+) and harboring ERBB2 G776_V777insVC demonstrated a partial response when treated with Kadcyla (ado-trastuzumab emtansine), with a duration of response of 7.3 months, a progression-free survival of 8.5 months, and an overall survival of 20.2 months (PMID: 30206164; NCT02289833).||30206164|